An industry spokesman dismissed the price data, suggesting that people should consider the drugs, higher prices and all, a form of savings. After all, said Ken Johnson, senior vice president of the Pharmaceutical Research and Manufacturers of America, that costly medicine might keep you out of an even-costlier hospital.If you buy that one, he’s earned his bonus.
More
1 comment:
This is a huge issue for the credibility of Canadian investigator-initiated science policy. We have always prided ourselves on the integrity and transparency of our peer-reviewed funding mechanisms. I would encourage all other members of the CIGR-GC to report all their affiliations. Then the obvious conflict of an appointment of a VP from a proven corrupt Big Pharma corporation will be there for all to see.
Post a Comment